Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar
- Written by PR Newswire
- Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations
- Henlius to receive $31 million upfront, and up to $270 million in milestones
SHANGHAI, April 29, 2025 /PRNewswire/ -- On April 29, 2025, Shanghai Henlius Biotech, Inc. (2696.HK) announced a licensing agreement...
Read more: Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar














